Future Fund LLC Has $504,000 Position in argenex SE $ARGX

Future Fund LLC increased its holdings in shares of argenex SE (NASDAQ:ARGX) by 24.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 915 shares of the company’s stock after purchasing an additional 179 shares during the period. Future Fund LLC’s holdings in argenex were worth $504,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the business. Lord Abbett & CO. LLC raised its holdings in argenex by 33.2% during the 1st quarter. Lord Abbett & CO. LLC now owns 274,700 shares of the company’s stock worth $162,585,000 after buying an additional 68,498 shares during the period. Millennium Management LLC increased its position in shares of argenex by 316.9% during the first quarter. Millennium Management LLC now owns 268,604 shares of the company’s stock worth $158,977,000 after acquiring an additional 204,180 shares in the last quarter. Jennison Associates LLC raised its holdings in shares of argenex by 6.1% during the second quarter. Jennison Associates LLC now owns 264,647 shares of the company’s stock worth $145,879,000 after acquiring an additional 15,186 shares during the period. Allspring Global Investments Holdings LLC lifted its position in argenex by 4.8% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 184,987 shares of the company’s stock valued at $100,350,000 after acquiring an additional 8,537 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in argenex by 14.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 168,765 shares of the company’s stock worth $99,886,000 after purchasing an additional 21,805 shares during the period. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenex Stock Performance

Shares of ARGX stock opened at $854.65 on Monday. The company has a market capitalization of $52.62 billion, a price-to-earnings ratio of 36.70, a PEG ratio of 0.89 and a beta of 0.45. argenex SE has a 52 week low of $510.05 and a 52 week high of $857.48. The company has a 50-day simple moving average of $782.86 and a 200 day simple moving average of $663.39.

argenex (NASDAQ:ARGX) last issued its quarterly earnings data on Thursday, October 30th. The company reported $4.40 EPS for the quarter, beating analysts’ consensus estimates of $4.37 by $0.03. argenex had a return on equity of 29.78% and a net margin of 41.58%.The firm had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.07 billion. Sell-side analysts forecast that argenex SE will post 3.13 EPS for the current year.

Analyst Ratings Changes

Several analysts have issued reports on the company. JPMorgan Chase & Co. lifted their price target on argenex from $830.00 to $925.00 and gave the company an “overweight” rating in a research note on Friday. Weiss Ratings reissued a “hold (c)” rating on shares of argenex in a research report on Wednesday, October 8th. Bank of America boosted their target price on argenex from $880.00 to $887.00 and gave the company a “buy” rating in a research note on Tuesday, September 2nd. Truist Financial raised their price target on shares of argenex from $700.00 to $918.00 and gave the stock a “buy” rating in a research note on Monday, September 15th. Finally, Jefferies Financial Group set a $818.00 price objective on shares of argenex and gave the stock a “buy” rating in a research report on Tuesday, August 26th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $869.68.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.